Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12338379 | 0.85 | ALDH1A1 (0.38) | BCHEACHEALDH1A1MAPK14KDM4E | |
| SCHEMBL21477577 | 0.76 | — | — | |
| SCHEMBL31300307 | 0.76 | PDE10A (0.47) | ALDH1A1KDM4ECYP1A2SMN1; SMN2NPSR1 | |
| SCHEMBL1102411 | 0.76 | PDE10A (0.47) | ALDH1A1KDM4ECYP1A2SMN1; SMN2NPSR1 | |
| SCHEMBL2928822 | 0.75 | BCHE (0.46) | BCHEACHEALDH1A1MAPK14KDM4E | |
| SCHEMBL1104821 | 0.75 | BCHE (0.54) | BCHEACHEALDH1A1MAPK14KDM4E | |
| SCHEMBL2611073 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL12338378 | 0.74 | — | — | |
| SCHEMBL15423517 | 0.73 | ALDH1A1 (0.40) | BCHEACHEALDH1A1MAPK14KDM4E | |
| SCHEMBL2611076 | 0.73 | ALDH1A1 (0.47) | ALDH1A1KDM4EOGALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-08-17 | — | — | US | disclosed |
| EP-3838897-A2 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021058592-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-9533986-B2 | Bicyclic dihydropyridone kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-9469654-B2 | Bicyclic oxa-lactam kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150266871-A1 | BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9040530-B2 | 1,2,4-triazine-6-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140323722-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-8754113-B2 | Oxadiazole derivative having endothelial lipase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | MAP2K2, MAP2K5, MAP2K4 | BCHE 4464/4885ACHE 3461/4885ALDH1A1 3315/4885 |
| US-20150266871-A1 | BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS | SYK, JAK2, ZAP70 | BCHE 4442/4885ACHE 4692/4885ALDH1A1 3414/4885 |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | SYK, BTK, JAK2 | BCHE 2611/4885ACHE 4230/4885ALDH1A1 4320/4885 |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | SYK, LCK, BTK | BCHE 4275/4885ACHE 4393/4885ALDH1A1 4736/4885 |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | LIPG, LPL, CEL | BCHE 281/4885ACHE 215/4885ALDH1A1 2861/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | BCHE 759/4885ACHE 2864/4885ALDH1A1 543/4885 |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | MAP2K2, MAP2K4, MAP2K5 | BCHE 4405/4885ACHE 3230/4885ALDH1A1 3270/4885 |
| US-20140323722-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | LIPG, CEL, LPL | BCHE 98/4885ACHE 84/4885ALDH1A1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.